medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 6

<< Back Next >>

Ann Hepatol 2017; 16 (6)

Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications

Hu RW, Carey EJ, Lindor KD, Tabibian JH

Language: Spanish
References: 75
Page: 835-841
PDF size: 217.90 Kb.


ABSTRACT

Curcumin, an aromatic phytoextract from the turmeric (Curcuma longa) rhizome, has been used for centuries for a variety of purposes, not the least of which is medicinal. A growing body of evidence suggests that curcumin has a broad range of potentially therapeutic pharmacological properties, including anti-inflammatory, anti-fibrotic, and anti-neoplastic effects, among others. Clinical applications of curcumin have been hampered by quality control concerns and limited oral bioavailability, although novel formulations appear to have largely overcome these issues. Recent in vitro and in vivo studies have found that curcumin's cytoprotective and other biological activities may play a role in an array of benign and malignant hepatobiliary conditions, including but not limited to non-alcoholic fatty liver disease, cholestatic liver disease (e.g. primary sclerosing cholangitis), and cholangiocarcinoma. Here we provide an overview of fundamental principles, recent discoveries, and potential clinical hepatobiliary applications of this pleiotropic phytocompound.


REFERENCES

  1. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012; 39: 283-99.

  2. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595: 1-7.

  3. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012; 26: 1719-25.

  4. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase- 2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001: 172: 111-8.

  5. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900.

  6. Singh S, Aggarwal BB. Activation of transcription factor NFkappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995; 270: 24995-5000.

  7. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin- phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155-63.

  8. Pulido-Moran M, Moreno-Fernández J, Ramírez-Tortosa C, Ramírez-Tortosa M. Curcumin and Health. Molecules 2016; 21: 264.

  9. Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y. Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. Int J Mol Sci 2016; 17:465.

  10. Vera-Ramírez L, Pérez-López P, Varela-López A, Ramírez- Tortosa M, Battino M, Quiles JL. Curcumin and liver disease. Biofactors 2013; 39: 88-100.

  11. Priyadarsini KI. Chemical and structural features influencing the biological activity of curcumin. Curr Pharm Des 2013; 19: 2093-100.

  12. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-18.

  13. Gupta SC, Patchva S, Aggarwal B. Therapeutic roles of Curcumin: lesions learned from clinical trials. The AAPS Journal 2013; 15: 195-218.

  14. Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC. Therapeutic Applications of Curcumin Nanoformulations. AAPS J 2015; 17: 1341-56.

  15. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014; 46: 2-18.

  16. Fan X, Zhang X, DB Liu, Yan J, Liang HP. The clinical applications of Curcumin: Current state and the future. Curr Phar Des 2013; 19: 2011-5.

  17. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005; 1056: 206-17.

  18. Singh S, Aggarwal BB. Activation of transcription factor NF- κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995-5000.

  19. Shih SC, Claffey KP. Role of AP-1 and HIF-1 transcription factorsin TGF-β activation of VEGF expression. Growth Factors 2001; 19: 19-34.

  20. Bachmeier BE, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, Dell'Eva R, et al. The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 2007; 19: 137-52.

  21. El-Azab F, Hishe H, Moustafa Y, El-Awady E. Anti-angiogenic effect of resveratrol and curcumin in ehrlich ascites carcinoma-bearing mice. Eur J Pharmacol 2011; 652: 7-14.

  22. Bassiouny AR, Zaky A, Fawky F, Kandeel K. Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats. Ann Hepatol 2011; 10: 516-30.

  23. Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Nov O, Ching JY, et al. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015; 13: 1444-9.

  24. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.

  25. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 2010; 103: 1545-57.

  26. Lin YL, Lin CY, Chi CW, Huang YT. Study on antifibrotic effects of curcumin in rat hepatic stellate cells. Phytother Res 2009; 23: 927-32.

  27. Nakayama N, Nakamura T, Okada H, Iwaki S, Sobel BE, Fujii S. Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-b. Coronary Artery Dis 2011; 22: 468-78.

  28. Ghosh N, Ghosh R, Mandal V, Mandal SC. Recent advances in herbal medicine for treatment of liver diseases. Pharm Biol 2011; 49: 970-88.

  29. Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG, Muriel P. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam Clin Pharm 2008; 22: 417-27.

  30. El Swefy S, Hasan RA, Ibrahim A, Mahmoud MF. Curcumin and hemopressin treatment attenuates cholestasis-induced liver fibrosis in rats: role of CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 103-16.

  31. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thuringer A, Leski K, et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010; 59: 521-30.

  32. Tabibian JH, Trussoni CE, O’Hara SP, Splinter PL, Heimbach JK, LaRusso NF. Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangititis. Lab Invest 2014; 94: 1126-33.

  33. Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangititis. Hepatology 2014; 59: 2263-75.

  34. Rao DS, Sekhara NC, Satyanarayana MN, Srinivasan M. Effect of curcumin on serum and liver cholesterol levels in the rat. J Nutr 1970; 100: 1307-15.

  35. Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM, Shin SK, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 2008; 57: 1576-83.

  36. Wang L, Lv Y, Yao H, Yin L, Shang J. Curcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reduction. Int J Clin Exp Pathol 2015; 8: 11503-9.

  37. Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil A, Quiles JL. Curcumin ameliorates rabbit's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic Biol Med 2009; 47: 924-31.

  38. Lee SJ, Kang JH, Iqbal W, Kwon OS. Proteomic analysis of mice fed methionine and choline deficient diet reveals marker proteins associated with steatohepatitis. PLoS One 2015; 7: 10.

  39. Rukkumani R, Sri Balasubashini M, Vishwanathan P, Menon VP. Comparative effects of curcumin and photo-irradiated curcumin onalcohol- and polyunsaturated fatty acid-induced hyperlipidemia. Pharmacol Res 2002; 46: 257-64.

  40. Rukkumani R, Aruna K, Varma PS, Viswanathan P, Rajasekaran KN, Menon VP. Protective role of a novel curcuminoid on alcohol and PUFA-Induced hyperlipidemia. Toxicol Mech Methods 2005; 15: 227-34.

  41. Guangwei X, Rongzhu L, Wenrong X, Suhua W, Xiaowu Z, Shizhong W, Ye Z, et al. Curcumin pretreatment protects against acute acrylonitrile-induced oxidative damage in rats. Toxicology 2010; 267: 140-6.

  42. Charoensuk L, Pinlaor P, Prakobwong S, Hiraku Y, Laothong U, Ruangjirachuporn W, Yongvanit P, et al. Curcumin induces a nuclear factor-erythroid 2-related factor 2-drivenresponse against oxidative and nitrative stress after praziquantel treatment in liver fluke-infected hamsters. Int J Parasitol 2011; 41: 615-26.

  43. Farombi EO, Shrotriya S, Na HK, Kim SH, Surh YJ. Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem Toxicol 2008; 46: 1279-87.

  44. Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 2014; 63: 1137-49.

  45. Waiyaput W, Payungporn S, Issara-Amphorn J, Panjaworayan NT. Inhibitory effects of crude extracts from some edible Thai plants against replication of hepatitis B virus and human liver cancer cells. BMC Complement Altern Med 2012; 12: 246.

  46. Shubha MC, Reddy RR, Srinivasan K. Antilithogenic influence of dietary capsaicin and curcumin during experimental induction of cholesterol gallstone in mice. Appl Physiol Nutr Metab 2011; 36: 201-9.

  47. Li Y, Li M, Wu S, Tian Y. Combination of curcumin and piperine prevents formation of gallstones in C57BL6 mice fed on lithogenic diet: whether NPC1L1/SREBP2 participates in this process? Lipids Health Dis 2015; 14: 100.

  48. Adhvaryu MR, Reddy N, Vakharia BC. Prevention of hepatotoxicity due to anti-tuberculosis treatment: a novel integrative approach. World J Gastroenterol 2008; 14: 4753-62.

  49. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 1999; 13: 245-9.

  50. Niederau C, Gopfert E. The effect of chelidonium- and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study. Med Klin (Munich)1999; 94: 425-30.

  51. Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, Hsieh CY, et al. Curcumin-containing diet inhibits diethylnitrosamine- induced murine hepatocarcinogenesis. Carcinogenesis 2000; 21: 331-5.

  52. Xiao J, Chu Y, Hu K, Wan J, Huang Y, Jiang C, Liang G, et al. Synthesis and biological analysis of a new Curcumin analogue for enhanced anti-tumor activity in HepG 2 cells. Oncol Rep 2010; 23: 1435-41.

  53. Jia L, Wang H, Qu S, Miao X, Zhang J. CD147 regulates vascular endothelial growth factor-A expression, tumorigenicity, and chemosensitivity to curcumin in hepatocellular carcinoma. IUBMB Life 2008; 60: 57-63.

  54. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett 2005; 224: 53-65.

  55. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Antiangiogenic activity of curcumin in hepatocellular carcinoma cells implanted nude mice. Clin Hemorheol Microcirc 2005; 33: 127-35.

  56. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 2006; 34: 109-15.

  57. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and anti-angiogenic effects of Curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol 2008; 14: 2003-9.

  58. Ohashi Y, Tsuchiya Y, Koizumi K, Sakurai H, Saiki I. Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology 2003; 65: 250-8.

  59. Piper JT, Singhal SS, Salameh MS, Torman RT, Awasthi YC, Awasthi S. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 1998; 30: 445-56.

  60. Sreepriya M, Bali G. Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital induced hepatocarcinogenesis in Wistar rats. Fitoterapia 2005; 76: 549-55.

  61. Sreepriya M, Bali G. Effects of administration of Embelin and Curcumin on lipid peroxidation, hepatic glutathione Antioxidant defense and hematopoietic system during N-nitrosodiethylamine/ Phenobarbital-induced hepatocarcinogenesis in Wistar rats. Mol Cell Biochem 2006; 284: 49-55.

  62. Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, et al. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochem Biophys Res Commun 2015; 468: 525-32.

  63. Prakobwong S, Gupta SC, Kim JH, Sung B, Pinlaor P, Hiraku Y, Wongkham S, et al. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 2011; 32: 1372-80.

  64. Suphim B, Prawan A, Kukongviriyapan U, Kongpetch S, Buranrat B, Kukongviriyapan V. Redox modulation and human bile duct cancer inhibition by curcumin. Food Chem Toxicol 2010; 48: 2265-72.

  65. Prakobwong S, Khoontawad J, Yongvanit P, Pairojkul C, Hiraku Y, Sithithaworn P, Pinlaor P, et al. Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int J Cancer 2011; 129: 88-100.

  66. Plengsuriyakarn T, Viyanant V, Eursitthichai V, Picha P, Kupradinun P, Itharat A, Na-Bangchang K. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med 2012; 12: 23.

  67. Lukita-Atmadja W, Ito Y, Baker GL, McCuskey RS. Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. Shock 2002; 17: 399- 403.

  68. Yun SS, Kim SP, Kang MY, Nam SH. Inhibitory effect of curcumin on liver injury in a murine model of endotoxemic shock. Biotechnol Lett 2010; 32: 209-14.

  69. Shapiro H, Ashkenazi M, Weizman N, Shahmurov M, Aeed H, Bruck R. Curcumin ameliorates acute thioacetamide-induced hepatotoxicity. J Gastroenterol Hepatol 2006; 21: 358-66.

  70. Bisht S, Khan MA, Bekhit M, Bai H, Cornish T, Mizuma M, Rudek MA, et al. A polymeric nanoparticle formulation of curcumin (NanoCurcTM) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab Invest 2011; 91: 1383-95.

  71. Mouzaoui S, Rahim I, and Djerdjouri B. Aminoguanidine and curcuminattenuated tumor necrosis factor (TNF)-a-induced oxidative stress, colitis and hepatotoxicity in mice. Int Immunopharmacol 2012; 12: 302-11.

  72. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001; 131: 2932-5.

  73. He SM, Chan E, Zhou SF. ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr Pharm Des 2011; 17: 357-407.

  74. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, et al. (2012) Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 2012; 69: 65-70.

  75. Mohandas KM, Desai DC. Epidemiology of digestive tract cancers in India. V. Large and small bowel. Indian J Gastroenterol 1999; 18(3): 118-21.




2020     |     www.medigraphic.com